ReviewClinical lymphoma, myeloma & leukemia2015

Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.

Elias Jabbour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.